| Project/Area Number |
16K11249
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
Kawata Ryo 大阪医科大学, 医学部, 教授 (40224787)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
栗栖 義賢 大阪医科大学, 医学部, 准教授 (30319529)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 耳下腺癌 / 顔面神経 / HER2 / AR / 生存率 / 新規治療 / 個別化治療 / バイオマーカー / 悪性度 / リンパ節転移 / EGFR / 外科 |
|---|
| Outline of Final Research Achievements |
The subjects were 171 patients with parotid carcinoma treated at our department during the 18-year.
15 patients were Human epidermal growth factor receptor type 2(HER2) positive and 92 patients were HER2 negative. HER2 positive patients had a significantly worse prognosis (p<0.001). There were 15 Androgen receptor (AR) positive patients and 92 AR negative patients. AR positive patients had also significantly worse prognosis (p<0.001). Salivary gland cancers are histologically similar to certain types of breast cancer. Use of anti-HER2 therapy is currently approved for HER2 overexpressing breast cancer, which has led to interest in studying anti-HER2 treatment for salivary gland cancers. Since advanced cancer has a poor prognosis with a limited response to surgery and radiation therapy, development of new treatment strategies, such as molecular-targeting therapies directed against HER-2 and AR is required.
|
| Academic Significance and Societal Importance of the Research Achievements |
耳下腺癌の予後は必ずしも良好ではなく、現状では手術以外に有効な手段がない。また顔面神経が耳下腺内を走行しており、その温存・切除により術後の生活の質（QOL）を大きく左右する。今回の研究において耳下腺癌に対して、新規薬物治療を探ることが、生命予後だけでなく患者のQOLに大きく貢献できると考えている。耳下腺癌に対する個別化治療を目指す。
|
